Using a special MRI scan to measure oxygen in liver cancer tumors
Tests BOLD MRI to measure tumor oxygen in adults with hepatocellular carcinoma.
Plain-language title generated from the registry record
Registry title: Characterizing Tumor Hypoxia With BOLD-MRI to Predict Y-90 Treatment Response
Key facts
- Where
- Chapel Hill, United StatesSee the site
Where in United States
- UNC Lineberger Comprehensive Cancer CenterChapel Hill, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UNC Lineberger Comprehensive Cancer Center
- Trial code
- NCT07916376
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to find out whether a special type of magnetic resonance imaging ( MRI), called blood oxygen level-dependent (BOLD) MRI, can help measure how much oxygen is present in liver tumors. Tumors with low oxygen levels are described as being hypoxic.Read full original descriptionShow less
Characterization of the Hypoxic Tumor Microenvironment With Blood Oxygen Level-Dependent Magnetic Resonance Imaging for the Prediction of Hepatocellular Carcinoma Response to Yttrium-90 Selective Internal Radiation Therapy
The purpose of this study is to find out whether a special type of magnetic resonance imaging ( MRI), called blood oxygen level-dependent (BOLD) MRI, can help measure how much oxygen is present in liver tumors. Tumors with low oxygen levels are described as being hypoxic.
Yttrium-90 (Y-90) is a type of radioactive material used to treat liver tumors, including hepatocellular carcinoma (HCC), a type of liver cancer. Y-90 is a form of radiation treatment delivered directly to liver tumors through tiny beads carried by blood vessels. These beads release radiation that damages and kills cancer cells while helping limit radiation exposure to surrounding healthy tissue. This treatment is also called Y-90 radioembolization or selective internal radiation therapy (SIRT).
Inclusion: Subjects must meet all the inclusion criteria to participate in this study; Adults ≥ 18 years; Liver mass(es) suspected of being HCC by imaging and are amenable to undergo percutaneous liver mass biopsy to confirm the HCC diagnosis, as determined by the institutional multidisciplinary tumor board; At least 1 tumor ≥ 2 cm and deemed to benefit from Y90 radioembolization by the institutional multidisciplinary tumor board; Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky Performance Status (KPS) ≥60%); Life expectancy ≥6 months, as determined by the investigator.
Exclusion: Definite liver transplant candidate; Concurrent secondary malignancy; All subjects meeting any of the exclusion criteria at baseline will be excluded from study participation; Distant metastasis.